New drug shows promise in slowing kidney damage for alport syndrome patients
Disease control
Completed
This study tested a drug called setanaxib in 20 people with Alport syndrome, a genetic condition that damages kidneys. The goal was to see if adding setanaxib to standard care is safe and helps preserve kidney function by reducing protein in urine. Participants took either setana…
Phase: PHASE1, PHASE2 • Sponsor: Calliditas Therapeutics AB • Aim: Disease control
Last updated May 26, 2026 12:03 UTC